Have any questions? 706-721-6582 or cts@augusta.edu
- BP1002-101-Lymph: A Phase 1 Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients with Advanced Lymphoid Malignancies
Clinical Trial
BP1002-101-Lymph: A Phase 1 Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients with Advanced Lymphoid Malignancies
The purpose of this study is to determine the highest dose of BP1002 that is tolerated by subjects. BP1002 is a drug that is injected into a vein (IV?intravenously) that causes cancer cells to die (in cell cultures). The study will also look at how safe BP1002 is by monitoring your heart (ECG and blood pressure) and other body systems (kidney, liver, and others), the amount of BP1002 in your blood at various time points, the activity of BP1002, the amount of anti-drug antibodies, and any potential side effects that you may experience.
Eligibility Criteria
- Inclusion criteria: Male and female patients aged 18 years or older Patient has life expectancy of 3 months or less. Relapsed Lymphoma Refractory Lymphoma Exclusion criteria: Patient eligible for high dose chemotherapy and autologous stem cell transplant. Patients at high risk of Tumor Lysis Syndrome (TLS) Uncontrolled active, untreated, or progressive infection Full inclusion/exclusion criteria may be found on ClinicalTrials.gov, or by contacting our clinical trials office.
RESEARCH. INNOVATION. DISCOVERY.